Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Treatment De-Escalation for Favorable Prognosis, Stage I-II Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

NCT06902623 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT06902623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06902623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Treatment De-Escalation for Favorable Prognosis, Stage I-II Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy
Lead sponsor
Georgetown University
Phase
Not applicable
Overall status
Recruiting
Start date
August 1, 2019
Completion date
December 31, 2030
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

base of tongue cancer, hpv, oropharyngeal cancers, tonsil cancer